Safety, Immunogenicity and Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine vs Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Admd as Booster Doses to Healthy Children 4-6 Yrs, Each co-Admd With Merck's MMR Vaccine.
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2016
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 01 Apr 2008 Primary endpoint 'Immunological response rate' has been met.
- 07 May 2007 Results were presented at the Pediatric Academic Societies (PAS) annual meeting.
- 05 Nov 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History